Your browser doesn't support javascript.
loading
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang, Michael L; Jain, Preetesh; Zhao, Shuangtao; Lee, Hun Ju; Nastoupil, Loretta; Fayad, Luis; Ok, Chi Young; Kanagal-Shamanna, Rashmi; Hill, Holly A; Yao, Yixin; Hagemeister, Fredrick B; Westin, Jason R; Fowler, Nathan; Samaniego, Felipe; Steiner, Raphael; Nair, Ranjit; Iyer, Swaminathan P; Navsaria, Lucy; Badillo, Maria; Feng, Lei; Xuelin, Huang; Nogueras Gonzalez, Graciela M; Xu, Guofan; Wagner-Bartak, Nicolaus; Thirumurthi, Selvi; Santos, David; Tang, Guilin; Lin, Pei; Wang, Sa A; Jorgensen, Jeff; Yin, C Cameron; Li, Shaoying; Patel, Keyur P; Vega, Francisco; Medeiros, L Jeffery; Flowers, Christopher R; Wang, Linghua.
Afiliação
  • Wang ML; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: miwang@mdanderson.org.
  • Jain P; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhao S; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee HJ; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nastoupil L; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fayad L; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ok CY; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kanagal-Shamanna R; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hill HA; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yao Y; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hagemeister FB; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Westin JR; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fowler N; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Samaniego F; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Steiner R; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nair R; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Iyer SP; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Navsaria L; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Badillo M; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xuelin H; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nogueras Gonzalez GM; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xu G; Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wagner-Bartak N; Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Thirumurthi S; Department of Gastroenterology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Santos D; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tang G; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin P; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang SA; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jorgensen J; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yin CC; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Li S; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel KP; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vega F; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Medeiros LJ; Department of Hemato-Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Flowers CR; Mantle Cell Research Group, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang L; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA.
Lancet Oncol ; 23(3): 406-415, 2022 03.
Article em En | MEDLINE | ID: mdl-35074072
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombocitopenia / Linfoma de Célula do Manto / Linfopenia Limite: Adult / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombocitopenia / Linfoma de Célula do Manto / Linfopenia Limite: Adult / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article